Biotech Values

[JJM760]

So you think ponatinib alone may ultimately support a share price 5x current level, or about a $20B market cap? I'm sorry but that sounds pretty silly to me. Show some specific numbers to back up that kind of estimate.

Unlike some here, I believe Ponatinib is going to achieve some serious percentage of the front line CML market. I think it is within reason to believe that 2 billion in sales for Ponatinib within 5 years is not outrageous. Would that not substantiate a 20 bil MC alone?

ALXN has 1 bil in sales with a 20 bil MC right this minute.

And we are still just talking about Ponatinib for CML alone. No other indications, no 113, no other compounds.